Citadel Advisors
FULC icon

Citadel Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Citadel Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$285K Sell
37,200
-32,600
-47% -$302K ﹤0.01% 10581
2025
Q4 		$789K Buy
+69,800
New +$710K ﹤0.01% 7947
2025
Q2 		– Sell
-13,800
Closed -$39.7K – 13386
2025
Q1 		$39.7K Buy
13,800
+2,000
+17% +$7.35K ﹤0.01% 12544
2024
Q4 		$55.5K Sell
11,800
-190,400
-94% -$702K ﹤0.01% 12285
2024
Q3 		$722K Buy
202,200
+177,100
+706% +$1.31M ﹤0.01% 7486
2024
Q2 		$156K Buy
25,100
+21,500
+597% +$163K ﹤0.01% 10296
2024
Q1 		$34K Sell
3,600
-4,100
-53% -$36.6K ﹤0.01% 12568
2023
Q4 		$52K Sell
7,700
-7,800
-50% -$34.6K ﹤0.01% 11747
2023
Q3 		$68.8K Buy
15,500
+1,200
+8% +$5.25K ﹤0.01% 11340
2023
Q2 		$47.2K Sell
14,300
-15,500
-52% -$45.5K ﹤0.01% 11866
2023
Q1 		$84.9K Buy
29,800
+6,800
+30% +$60.9K ﹤0.01% 11488
2022
Q4 		$167K Buy
23,000
+5,500
+31% +$35.9K ﹤0.01% 10433
2022
Q3 		$142K Sell
17,500
-7,700
-31% -$55.1K ﹤0.01% 10769
2022
Q2 		$123K Sell
25,200
-5,400
-18% -$52.8K ﹤0.01% 11185
2022
Q1 		$724K Buy
30,600
+8,500
+38% +$120K ﹤0.01% 8486
2021
Q4 		$391K Sell
22,100
-700
-3% -$13.9K ﹤0.01% 10276
2021
Q3 		$643K Buy
+22,800
New +$432K ﹤0.01% 9272

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citadel Advisors's FULC Position: Q1 2026 in Review

Citadel Advisors increased its Fulcrum Therapeutics (FULC) stake by 7.1% in Q1 2026, buying an estimated $793K and bringing the position to 1,292,486 shares worth $9.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Citadel Advisors first reported a position in FULC in Q2 2021 and has held it in 20 quarters since. The position peaked at $13.7M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Citadel Advisors held 1,292,486 shares of Fulcrum Therapeutics worth $9.91M as of Q1 2026.
  • Citadel Advisors bought 85,482 Fulcrum Therapeutics shares in Q1 2026, an estimated $793K.
  • Fulcrum Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3271 holding.
  • Citadel Advisors first reported a position in Fulcrum Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Fulcrum Therapeutics position peaked at $13.7M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.